CL Q3 2026 Earnings Analysis
Q3 organic growth led by emerging markets and Hill's Pet (+6.5%) with 200 bps pricing offsetting 300 bps inflation; North America restructured toward premium innovation.
Key Metrics
Key Takeaways
- Emerging markets and Hill's Pet (+6.5%) lead organic growth amid 300 bps material inflation cost pressures.
- Pricing (200 bps Q3) and funding-the-growth offset costs; restructuring North America toward premium innovation.
- Free cash flow up 7%; $2.2B returned to shareholders YTD; cost pressures expected into early 2027.
Listen On
Available In
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.
And I'm Jordan. Today we're digging into Colgate-Palmolive's third quarter 2026 results, reported on October 30th.
Before we get into it, quick disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Alright, with that out of the way—Alex, this was actually a pretty strong quarter for a company that's been dealing with a lot of noise.
Yeah, let's start with the big picture. Colgate posted organic sales growth across four of its five divisions and all four product categories—oral care, personal care, home care, and pet nutrition. That's broad-based, which matters because it means they're not leaning on just one hot business line.
And the margin story is honestly the headline here. They faced a 300 basis point headwind from material inflation—that's resins, petrochemicals, pulp and paper, all elevated—but their productivity programs, "funding-the-growth" and this newer "Strategic Growth and Productivity Program," offset nearly all of it. CFO Stan Sutula said funding-the-growth alone delivered over 290 basis points of offset.
So basically a near-perfect hedge against inflation through internal efficiency rather than just jacking up prices.
Right, and pricing still played a role too—80 basis points of favorable pricing, plus 20 basis points from mix. They've taken pricing every quarter this year: 220 basis points in Q1, 160 in Q2, 200 in Q3. They're clearly trying to stay ahead of the cost curve rather than react to it.
Free cash flow was up 7% year-to-date, and they've returned $2.2 billion to shareholders so far this year. That's a healthy capital return story even with all this cost volatility swirling around.
Let's talk geography, because that's really where the story gets interesting. Emerging markets grew mid-single digits, led by India, Brazil, and China.
India was a standout—double-digit growth again, driven by premium innovation. China's trickier—the category itself is soft, lots of brick-and-mortar weakness, but Colgate's own China business grew high single digits by leaning hard into e-commerce and social platforms like Douyin.
And Hill's Pet Nutrition—wow. Organic sales up 6.5% ex-private label. Prescription Diet cat was up double digits, dog up mid-single digits. The therapeutic side is really firing, and it's creating a halo effect on the wellness side of that business.
They also teased their "Fresh" line—the fresh pet food push with chicken and brown rice, beef and carrot, lamb and pumpkin diets. CEO Noel Wallace was clear they're rolling that out slowly and deliberately, protecting the Hill's brand reputation with vets rather than rushing for a quick win.
Now, let's get to the part analysts clearly wanted more color on: the U.S. turnaround. This was a recurring theme in the Q&A.
Right, multiple analysts—Filippo Falorni, Andrea Teixeira—pushed on North America. Wallace acknowledged some green shoots in toothpaste market share, but was candid that this is a multi-quarter rebuild, not a quick fix.
The structural piece was fascinating to me. Colgate is literally restructuring their North American go-to-market model—moving away from a traditional channel-based structure toward one built around digital, social, and what Wallace called "agentic commerce" connections. His quote was something like: the business was built for "a world of channels," but we're now in "a world that runs on connections."
That's a pretty bold admission that their old commercial structure is outdated for how consumers actually shop now.
And it ties into premium innovation—Wallace noted that premium and super-premium toothpaste segments are growing at 2-3 times the rate of mid-price and value tiers. So the U.S. strategy next year is really about getting premium products seeded effectively and using AI-driven personalization to make advertising spend work harder.
Speaking of advertising—they've increased ad spend about 40% over four years, and when Dara Mohsenian from Morgan Stanley asked about ROI, Wallace was confident, pointing to market share gains across toothpaste, toothbrushes, and mouthwash globally as proof it's working.
One regional wrinkle worth flagging: Latin America overall grew 6%, Brazil was up double digits, but Mexico slowed due to a tough consumer backdrop and some specific retailer challenges. Management expects that to persist into Q4 but resolve heading into 2027.
And on the cost side—Sutula reiterated that cost inflation is still running around $300 million, consistent with prior guidance, with Q4 expected to be the peak quarter for both commodity costs and logistics expenses as a percentage of sales.
They also declined to give any real 2027 guidance—that classic "we'll address that in Q1" answer—but Wallace did flag that FX has started moving against them recently, and tariff impacts are expected to peak in Q4.
So what does this mean for investors going forward? I'd say the takeaway is: Colgate is executing well on what it can control—productivity, pricing discipline, premiumization—while navigating real external pressure from commodities and FX that it can't control.
Exactly. The emerging markets and Hill's engine keeps humming, Europe is quietly performing well with record shares, and the U.S. turnaround is a real multi-quarter project rather than a switch that's been flipped. Watch Q4 and early 2027 guidance for whether that premium innovation pipeline in North America actually translates into share gains.
Oh, and one fun closing note from the call—Colgate's longtime IR exec Hope Spiller is retiring after 103 quarters of earnings calls with the company. That's over 25 years of earnings season. Respect.
That's dedication. Before we wrap, our standard reminder: Everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Looking ahead, keep an eye on how Mexico stabilizes, whether U.S. toothpaste share gains continue building, and what tone management sets heading into that 2027 guidance in Q1.
This has been Beta Finch. Thanks for listening, and we'll catch you on the next earnings breakdown.
Take care, everyone.